Provided herein are methods and compositions related to Prevotella bacteria for the reduction of IL-8, IL-6, IL-Iβ, and/C or TNFα expression and/or for the treatment of viral infections.

Disclosed herein are GABA.sub.A receptor modulators and compositions comprising GABA.sub.A receptor modulators for treatment of epileptic conditions. Also disclosed herein are methods of treating epileptic conditions in a subject by administering a GABA.sub.A receptor modulators or composition as described herein.

Disclosed herein are GABA.sub.A receptor modulators and compositions comprising GABA.sub.A receptor modulators for treatment of epileptic conditions. Also disclosed herein are methods of treating epileptic conditions in a subject by administering a GABA.sub.A receptor modulators or composition as described herein.

The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.

The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.

Compositions and methods for selective mTOR inhibition and/or increase of autophagy in a tissue of a subject have been developed for the treatment of cancer. Caged mTOR inhibitor prodrugs including photo-cleavable protecting groups are provided for selective chemotherapy through an optochemical treatment system. Pharmaceutical compositions of mTOR inhibitors that are deactivated (caged) with a photo-removable protecting group to controllably block the inhibitory activity of the inhibitor are provided. The photo-removable group is cleavable upon exposure to light irradiation, releasing the active inhibitor of mTOR signaling and autophagy at the site of irradiation. An exemplary caged mTOR inhibitor prodrug is a caged OSI-027 prodrug having a DEACM moiety bound thereto (cOSI-027). The cOSI-027 is activated in the region of a tumor by removal of the DEACM protecting group by exposure to light at 420 nm.

Compositions and methods for selective mTOR inhibition and/or increase of autophagy in a tissue of a subject have been developed for the treatment of cancer. Caged mTOR inhibitor prodrugs including photo-cleavable protecting groups are provided for selective chemotherapy through an optochemical treatment system. Pharmaceutical compositions of mTOR inhibitors that are deactivated (caged) with a photo-removable protecting group to controllably block the inhibitory activity of the inhibitor are provided. The photo-removable group is cleavable upon exposure to light irradiation, releasing the active inhibitor of mTOR signaling and autophagy at the site of irradiation. An exemplary caged mTOR inhibitor prodrug is a caged OSI-027 prodrug having a DEACM moiety bound thereto (cOSI-027). The cOSI-027 is activated in the region of a tumor by removal of the DEACM protecting group by exposure to light at 420 nm.

Provided is a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and cancer including colorectal cancer.

A compound represented by the formula [I] or a pharmaceutically acceptable salt thereof:

##STR00001##

wherein each symbol is as defined in the SPECIFICATION.

Provided is a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and cancer including colorectal cancer.

A compound represented by the formula [I] or a pharmaceutically acceptable salt thereof:

##STR00001##

wherein each symbol is as defined in the SPECIFICATION.

Provided is a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and cancer including colorectal cancer.

A compound represented by the formula [I] or a pharmaceutically acceptable salt thereof:

##STR00001##

wherein each symbol is as defined in the SPECIFICATION.